US approves gene therapy treatment for hemophilia
Pharmaceutical giant Pfizer has received US approval for a gene therapy against a form of hemophilia, a rare and inherited blood clotting disorder, the company said Friday. Pfizer's genetic therapy targets hemophilia B, the second most common form of the condition, which primarily affects males.